Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Adrenocortical Carcinoma

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Adrenocortical Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
Corcept Therapeutics
Phase 2B
Nivolumab
Dana-Farber Cancer Institute
Phase 2B
Cyclophosphamide
Anusha Kalbasi
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B

View all 43 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →